HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wester, H.-J. Articles by Bartenstein, P. Search for Related Content PubMed PubMed Citation Articles by Wester, H.-J. Articles by Bartenstein, P.

6-O-(2-[¹⁸F]Fluoroethyl)-6-O-Desmethyldiprenorphine ([¹⁸F]DPN): Synthesis, Biologic Evaluation, and Comparison with [¹¹C]DPN in Humans

Departments of Nuclear Medicine and Neurology, Technische Universität München, Munich
Max-Plank Institute of Psychiatry, Munich, Germany
Department of Pharmacology, University of Oslo, Oslo, Norway

Correspondence: For correspondence or reprints contact: Hans-J. Wester, PhD, Department of Nuclear Medicine, Technische Universität München, Ismaningerstr. 22, 81675 München, Germany.

ABSTRACT

6-O-(2-[¹⁸F]fluoroethyl)-6-O-desmethyldiprenorphine ([¹⁸F]DPN) was developed and biologically evaluated. Results of animal experiments, binding studies in vivo, and a human PET study are reported and compared with those of [¹¹C]DPN. Methods: [¹⁸F]DPN was obtained by ¹⁸F-fluoroethylation of 3-O-trityl-6-O-desmethyldiprenorphine and subsequent deprotection in good radiochemical yields (23% ± 7%; 100 min; 37 TBq/mmol). Binding of [¹⁸F]DPN to µ, , and opioid receptors was shown by autoradiograpny studies on rat brain slices. Quantification of cerebral opioid receptor binding in men was performed by spectral analysis of a dynamic PET scan (25 frames, 90 min) after intravenous application of 63 MBq [¹⁸F]DPN (36 GBq/µmol) and correction for metabolites. Results: [¹⁸F]DPN shows high affinity to opioid receptors. Parametric images (impulse response function at 60 min) of this human study showed a binding pattern of [¹⁸F]DPN equal to that of a control group (n = 9 healthy volunteers) after administration of [¹¹C]DPN. Conclusion: The advantage of the longer half-life of ¹⁸F will allow extended scanning periods, more flexible interventions (e.g., displacement studies), and DPN to be available to PET centers without an on-site cyclotron.

Key Words: diprenorphine • ¹⁸F • PET • opioids • [¹⁸F]DPN

This article has been cited by other articles:

				M. Schreckenberger, A. Klega, G. Grunder, H.-G. Buchholz, A. Scheurich, R. Schirrmacher, E. Schirrmacher, C. Muller, G. Henriksen, and P. Bartenstein Opioid Receptor PET Reveals the Psychobiologic Correlates of Reward Processing J. Nucl. Med., August 1, 2008; 49(8): 1257 - 1261. [Abstract] [Full Text] [PDF]

				H. Boecker, T. Sprenger, M. E. Spilker, G. Henriksen, M. Koppenhoefer, K. J. Wagner, M. Valet, A. Berthele, and T. R. Tolle The Runner's High: Opioidergic Mechanisms in the Human Brain Cereb Cortex, February 21, 2008; (2008) bhn013v1. [Abstract] [Full Text] [PDF]

				S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]

				M. Martin, R. A. Hurley, and K. H. Taber Is Opiate Addiction Associated With Longstanding Neurobiological Changes? J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 242 - 248. [Full Text] [PDF]

				H. Boecker, T. Sprenger, G. Henriksen, T. R. Toelle, and M. E. Spilker Optimal Duration of PET Studies with 18F-Fluoroethyl-Diprenorphine J. Nucl. Med., December 1, 2005; 46(12): 2092 - 2096. [Abstract] [Full Text] [PDF]